Heron Therapeutics Statistics
Total Valuation
HRTX has a market cap or net worth of $154.09 million. The enterprise value is $248.10 million.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, before market open.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HRTX has 188.54 million shares outstanding. The number of shares has increased by 9.35% in one year.
| Current Share Class | 188.54M |
| Shares Outstanding | 188.54M |
| Shares Change (YoY) | +9.35% |
| Shares Change (QoQ) | +10.38% |
| Owned by Insiders (%) | 0.70% |
| Owned by Institutions (%) | 54.98% |
| Float | 133.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.99 |
| Forward PS | 1.83 |
| PB Ratio | 11.59 |
| P/TBV Ratio | 11.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.48, with a Debt / Equity ratio of 9.81.
| Current Ratio | 2.48 |
| Quick Ratio | 1.42 |
| Debt / Equity | 9.81 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.26 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -0.65% |
| Return on Invested Capital (ROIC) | -1.06% |
| Return on Capital Employed (ROCE) | -1.59% |
| Weighted Average Cost of Capital (WACC) | 8.53% |
| Revenue Per Employee | $1.21M |
| Profits Per Employee | -$157,773 |
| Employee Count | 128 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 0.58 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.04% in the last 52 weeks. The beta is 1.30, so HRTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.30 |
| 52-Week Price Change | -67.04% |
| 50-Day Moving Average | 1.21 |
| 200-Day Moving Average | 1.42 |
| Relative Strength Index (RSI) | 24.49 |
| Average Volume (20 Days) | 2,363,170 |
Short Selling Information
The latest short interest is 37.13 million, so 19.70% of the outstanding shares have been sold short.
| Short Interest | 37.13M |
| Short Previous Month | 35.36M |
| Short % of Shares Out | 19.70% |
| Short % of Float | 27.76% |
| Short Ratio (days to cover) | 23.16 |
Income Statement
In the last 12 months, HRTX had revenue of $154.90 million and -$20.20 million in losses. Loss per share was -$0.12.
| Revenue | 154.90M |
| Gross Profit | 112.52M |
| Operating Income | -2.54M |
| Pretax Income | -20.20M |
| Net Income | -20.20M |
| EBITDA | -224,000 |
| EBIT | -2.54M |
| Loss Per Share | -$0.12 |
Full Income StatementBalance Sheet
The company has $46.63 million in cash and $140.64 million in debt, with a net cash position of -$94.01 million or -$0.50 per share.
| Cash & Cash Equivalents | 46.63M |
| Total Debt | 140.64M |
| Net Cash | -94.01M |
| Net Cash Per Share | -$0.50 |
| Equity (Book Value) | 14.33M |
| Book Value Per Share | 0.07 |
| Working Capital | 141.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$27.59 million and capital expenditures -$317,000, giving a free cash flow of -$27.91 million.
| Operating Cash Flow | -27.59M |
| Capital Expenditures | -317,000 |
| Free Cash Flow | -27.91M |
| FCF Per Share | -$0.15 |
Full Cash Flow StatementMargins
Gross margin is 72.64%, with operating and profit margins of -1.64% and -13.04%.
| Gross Margin | 72.64% |
| Operating Margin | -1.64% |
| Pretax Margin | -13.04% |
| Profit Margin | -13.04% |
| EBITDA Margin | -0.14% |
| EBIT Margin | -1.64% |
| FCF Margin | n/a |
Dividends & Yields
HRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.35% |
| Shareholder Yield | -9.35% |
| Earnings Yield | -13.11% |
| FCF Yield | -18.11% |
Analyst Forecast
The average price target for HRTX is $4.50, which is 450.59% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.50 |
| Price Target Difference | 450.59% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 16.72% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 13, 2014. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 13, 2014 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
HRTX has an Altman Z-Score of -8.7 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.7 |
| Piotroski F-Score | 4 |
